Lupin expects muted growth in the US despite new launches

About 25 products to be launched next year will only partly compensate price erosion

Nilesh Gupta, managing director for Mumbai-based pharma major Lupin, is trying to reset investors expectation as its mojo in the US market is set to get weaker in the near term.

The company, which reported Rs 12,958 crore revenue in the nine months of the current financial year, earns about 48 per cent from the US markets.

“With one of the strongest pending pipelines in the US at its disposal, the company is well poised to address the pricing issue,” said Siddhant Khandekar, an analyst with ICICI Securities, in a recent report. “We expect US sales to grow at 18 per